Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
55M
-
Number of holders
-
90
-
Total 13F shares, excl. options
-
35.4M
-
Shares change
-
+1.13M
-
Total reported value, excl. options
-
$848M
-
Value change
-
+$26.4M
-
Number of buys
-
46
-
Number of sells
-
-38
-
Price
-
$23.99
Significant Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q4 2021
108 filings reported holding STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q4 2021.
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) has 90 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35.4M shares
of 55M outstanding shares and own 64.28% of the company stock.
Largest 10 shareholders include Skorpios Trust (14.4M shares), RTW INVESTMENTS, LP (3.64M shares), FMR LLC (2.55M shares), Redmile Group, LLC (2.25M shares), VANGUARD GROUP INC (1.91M shares), BlackRock Inc. (1.48M shares), Cormorant Asset Management, LP (1.18M shares), GILDER GAGNON HOWE & CO LLC (1.07M shares), STATE STREET CORP (797K shares), and Octagon Capital Advisors LP (784K shares).
This table shows the top 90 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.